Stockscreener 앱 받기
21.75
3.44%
-0.78
전일 마감가:
$22.53
열려 있는:
$22.52
하루 거래량:
315.35K
Relative Volume:
0.35
시가총액:
$2.69B
수익:
$434.48M
순이익/손실:
$68.15M
주가수익비율:
21.53
EPS:
1.01
순현금흐름:
$114.96M
1주 성능:
-0.80%
1개월 성능:
-0.62%
6개월 성능:
+34.45%
1년 성능:
+46.79%
1일 변동 폭
$21.71
$22.59
1주일 범위
$21.63
$23.02
52주 변동 폭
$13.00
$24.27
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.75 | 2.69B | 434.48M | 68.15M | 114.96M | 0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.01 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.25 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.60 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.38 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.63 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Martingale Asset Management L P Buys New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Walleye Capital LLC Invests $4.94 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Insiders At Catalyst Pharmaceuticals Sold US$4.4m In Stock, Alluding To Potential Weakness - Simply Wall St
Intech Investment Management LLC Purchases New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Gary Ingenito Sells 12,000 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director Sells 17,500 Shares of Stock - MarketBeat
Catalyst Pharmaceuticals executive sells shares worth $272,654 By Investing.com - Investing.com Canada
Catalyst Pharmaceuticals director Harper sells $385,000 in stock By Investing.com - Investing.com Nigeria
Catalyst Pharmaceuticals chief compliance officer sells $286,703 in stock - Investing.com India
Catalyst Pharmaceuticals director Harper sells $385,000 in stock - Investing.com
Catalyst Pharmaceuticals chief compliance officer sells $286,703 in stock By Investing.com - Investing.com UK
Capstone Investment Advisors LLC Takes $708,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
FORA Capital LLC Takes $516,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Recognized as One of North - GlobeNewswire
Segall Bryant & Hamill LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock - Investing.com India
Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals chairman sells $3.6 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Insider Trades Send A Signal - Benzinga
Pacer Advisors Inc. Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Quest Partners LLC Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals chairman sells $3.6 million in stock - Investing.com
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue? - MSN
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan
GSA Capital Partners LLP Invests $625,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at Stephens - MarketBeat
Principal Financial Group Inc. Sells 63,273 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals chairman sells shares worth $3.1 million - Investing.com
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock - Benzinga
Catalyst Pharmaceuticals chairman sells $11.5 million in stock - Investing.com
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times
Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance
Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50 - MarketBeat
CWA Asset Management Group LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio Management - MarketBeat
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.92%
자본화:
|
볼륨(24시간):